The HERO Act establishes a competitive grant program at HHS to help schools — including private schools, charter LEAs, and traditional local educational agencies — purchase opioid overdose reversal drugs approved under the Federal Food, Drug, and Cosmetic Act and to develop related educational programming. Grants last one year; applicants must commit to developing staff emergency response plans with local health departments and to provide CPR, prevention, and overdose-response education.
The bill also conditions receipt of federal funds on reporting every school distribution of an opioid overdose reversal drug to two federal information systems (NEMSIS and ODMAP) within 90 days of enactment and sets deadlines for recipient reporting to HHS and for HHS reporting to Congress. The measure prioritizes applicants in cities or counties with high opioid overdose rates, but it leaves key implementation choices — funding levels, technical guidance for reporting, and long‑term sustainability of supplies and training — to agency rulemaking and program design.
At a Glance
What It Does
Creates a competitive grant program at HHS (through the Assistant Secretary for Mental Health and Substance Use) to fund the purchase of FDA‑approved opioid overdose reversal drugs and related educational programming; grants run for one year. Requires schools that receive federal funds to report any distribution of such drugs to NEMSIS and ODMAP, starting within 90 days of enactment.
Who It Affects
Local educational agencies (including charter LEAs), private elementary and secondary schools, state and local health departments (in a consultative role), and HHS and Department of Education staff who will administer the program and analyze reports.
Why It Matters
This bill moves overdose response resources and incident data into both school settings and national EMS surveillance systems, potentially changing how public health and education sectors coordinate on opioid events. It creates short‑term funding and a reporting infrastructure that could inform real‑time public health responses — but it also imposes operational and data‑sharing demands on schools.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill charges the Assistant Secretary for Mental Health and Substance Use at HHS, working with the Secretary of Education, to run a competitive grants program aimed at supplying schools with opioid overdose reversal drugs that have FDA approval under section 505. Eligible applicants include private elementary and secondary schools as well as local educational agencies and consortia; charter schools are treated either as private schools or as LEAs depending on their legal status.
Grants explicitly cover the purchase of the reversal drug and the development or implementation of educational materials on CPR, drug‑use prevention, intervention, and overdose emergency response.
Applicants must submit a written plan explaining how they will use the funds and must provide assurances that they will consult with local health departments to develop comprehensive emergency response plans for school staff. For private schools the plan covers that school's staff; for LEAs the plan must cover each school the agency serves.
The statute gives awarding priority to applicants located in cities or counties with high opioid overdose rates, but it leaves the definition of “high rate” and the size of awards to the Secretary’s discretion.Grants are one year in length. Recipients must report back to HHS within one year after the grant period ends with three deliverables: how the reversal drugs were used, the emergency response plan developed, and the educational programming implemented.
Separately, the bill requires any covered educational institution that receives federal funds to submit a description of any distribution of an opioid overdose reversal drug to two federal data systems: NEMSIS (the national EMS information system) and ODMAP (the Washington/Baltimore HIDTA mapping application). That reporting requirement kicks in no later than 90 days after enactment.Finally, HHS must synthesize information it receives from grantees and produce a summary report to Congress beginning two years after enactment and then annually.
The bill defines covered institutions and eligible entities by reference to standard ESEA definitions, which aligns eligibility and reporting obligations with existing federal education categories but also means entities will need to reconcile school‑level practices with EMS data standards and reporting workflows.
The Five Things You Need to Know
The Secretary of HHS must start awarding competitive grants within 90 days of enactment, and each grant covers a 1‑year period.
Eligible entities are private elementary/secondary schools and local educational agencies (including charter LEAs); consortia of LEAs may apply.
Grant funds may only be used to purchase opioid overdose reversal drugs approved under 21 U.S.C. §355 (section 505) and to develop/implement related educational programming.
Schools receiving federal funds must report every distribution of an opioid overdose reversal drug to NEMSIS and to ODMAP, with the reporting obligation effective within 90 days of enactment.
Grant recipients must submit to HHS, within one year after the grant ends, descriptions of drug use, the emergency response plan developed with local health departments, and the educational programming delivered; HHS must then report summaries to Congress starting two years after enactment and annually thereafter.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the Act as the 'Helping Educators Respond to Overdoses Act' or 'HERO Act.' This is purely stylistic but signals the policy focus for implementing agencies and stakeholders.
Establishes HHS competitive grant program and application requirements
Directs the Assistant Secretary for Mental Health and Substance Use (HHS) to award competitive grants to eligible entities to buy FDA‑approved opioid reversal drugs and to support educational programming. Applications must describe intended use, include assurances of consultation with the local health department, and commit to developing staff emergency response plans and educational resources (CPR, prevention, intervention, overdose response). Practically, applicants will need to assemble program plans, local health partnerships, and curricula to be competitive.
Priority, grant period, and reporting back to HHS
The statute prioritizes applicants in cities/counties with high opioid overdose rates and sets each grant to a one‑year term. Recipients must report to the Secretary within one year after the grant period with three items: how drugs were used, the emergency response plan, and the educational programming delivered. The Secretary must consolidate those submissions and produce an initial Congressional report two years after enactment and annual reports thereafter. Agencies will need to decide metrics for 'high rate' areas and standardize grantee reporting templates.
Definitions aligning eligibility to ESEA terms
Defines 'eligible entity' and other covered terms by cross‑reference to the Elementary and Secondary Education Act (ESEA) definitions for elementary/secondary schools and LEAs, and adopts ESEA's definition of 'charter school.' That choice streamlines eligibility determinations but requires implementers to map education classifications to public‑health grant processes.
Requires reporting of school distributions to NEMSIS and ODMAP
Mandates that any covered educational institution receiving federal funds submit descriptions of any distribution of an opioid overdose reversal drug to the National EMS Information System (NEMSIS) and to the ODMAP system operated by the Washington/Baltimore HIDTA. The technical and privacy specifications for those reports are not in the text, so agencies will need to provide guidance and possibly build interfaces so schools can feed incident data into systems designed primarily for EMS agencies and public health partners.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Students and school staff in high‑overdose communities — increased on‑site access to FDA‑approved opioid reversal drugs and standardized emergency response planning improve immediate overdose survivability and preparedness.
- Local educational agencies and private schools that lack budget flexibility — one‑year grants can cover initial purchase of reversal drugs and pay for training and educational materials they otherwise could not afford.
- Public health surveillance and EMS planners — mandatory reporting to NEMSIS and ODMAP provides additional, school‑based overdose data that can enhance situational awareness and resource allocation.
- Local health departments — the consultation role formalizes partnerships with schools, creating clearer lines for training, plan development, and shared response protocols.
Who Bears the Cost
- School districts and private schools — implementing emergency plans, providing staff training, maintaining drug supplies (storage, rotation of expired product), and meeting reporting requirements impose administrative and operational costs beyond the grant term.
- HHS and Education departments — program design, grant administration, issuing technical guidance for reporting, and producing statutory summaries will require agency resources and interagency coordination.
- Small private schools and small LEAs — even with grant funding, these entities may face disproportionate compliance burdens to build reporting workflows and to consult with public health partners.
- State and local health departments and EMS systems — expected to consult on emergency plans and to integrate school incident reports into existing surveillance and response workflows, potentially stretching capacity.
Key Issues
The Core Tension
The bill balances two legitimate objectives — expanding immediate access to life‑saving opioid reversal drugs in school settings and improving public‑health data through mandatory reporting — but the mechanisms that enable rapid access (short, one‑year grants and decentralized reporting) create administrative, privacy, and sustainability burdens for schools and public‑health agencies that the text does not resolve.
The bill creates useful short‑term funding and a reporting requirement but leaves core operational choices to HHS rulemaking or program guidance. It does not specify grant amounts, eligibility scoring criteria, data elements or formats for reporting to NEMSIS/ODMAP, or how schools should authenticate or transmit incident reports.
Those omissions create implementation risk: schools will need technical assistance to map school incident data to EMS data standards and to protect privacy while meeting reporting obligations.
A key practical concern is sustainability. Grants are limited to one year but the public‑health need for reversal drugs and ongoing training is continuous.
Without explicit authorization for multi‑year funding or replenishment mechanisms, schools risk running out of supplies when grant funding ends. The bill also raises unresolved legal and privacy questions about reporting student‑related incidents into national surveillance systems designed for EMS, including how to de‑identify data and reconcile FERPA, HIPAA, and state privacy rules.
Finally, the bill prioritizes high‑overdose jurisdictions but says nothing about technical or capacity support for smaller districts that may be ill-equipped to comply.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.